FindTrial
Sign In

A single-center retrospective clinical study on the efficacy and safety of upadacitinib in the treatment of inflammatory myopathy with positive anti-melanoma differentiation-associated gene 5 (MDA5) antibody

A single-center retrospective clinical study on the efficacy and safety of upadacitinib in the treatment of inflammatory myopathy with positive anti-melanoma differentiation-associated gene 5 (MDA5) antibody

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111016
Enrollment
Unknown
Registered
2025-10-23
Start date
2025-10-24
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory myopathy

Interventions

Inflammatory Myopathy Observation Group:None

Sponsors

The First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged over 18 years old, both men and women are eligible; 2.Positive result of qualitative detection for anti-MDA5 antibody; 3.with interstitial lung disease; 4.reatment based on traditional hormones and/or immunosuppressants combined with upadacitinib;

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Dlco;FVC;Progression-free survival rate;—

Secondary

MeasureTime frame
Lung CT score;—

Countries

China

Contacts

Public ContactXudong Liu

The First Affiliated Hospital of China Medical University

2418264813@qq.com+86 24 8328 2549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026